Dabigatran

Research use only, not for human use.

A reversible and selective, direct thrombin inhibitor (DTI) with Ki value of 4.5 nM.

A reversible and selective, direct thrombin inhibitor (DTI) with Ki value of 4.5 nM; an anticoagulant agent used to prevent stroke with atrial fibrillation.Thrombosis Approved(In Vitro):Dabigatran (BIBR 953) shows concentration-dependent anticoagulant effects in various species in vitro, doubling the activated partial thromboplastin time (aPTT), prothrombin time (PT) and ecarin clotting time (ECT) in human platelet-poor plasma at concentrations of 0.23, 0.83 and 0.18 μM, respectively.(In Vivo):Dabigatran (0.01-0.1 mg/kg; i.v.) inhibits clot formation with an ED50 of 0.033 mg/kg in Wessler model.

Dabigatran (BIBR 953) shows concentration-dependent anticoagulant effects in various species in vitro, doubling the activated partial thromboplastin time (aPTT), prothrombin time (PT) and ecarin clotting time (ECT) in human platelet-poor plasma at concentrations of 0.23, 0.83 and 0.18 μM, respectively.

Dabigatran (0.01-0.1 mg/kg; i.v.) inhibits clot formation with an ED50 of 0.033 mg/kg in Wessler model. Animal Model:Male rats (Wessler model)Dosage:0.01, 0.03, 0.05 and 0.1 mg/kg Administration:Intravenous injection Result:Inhibited clot formation with an ED50 of 0.033 mg/kg.

BIBR 953 | BIBR 953ZW | BIBR953 | BIB-953

Autophagy

Thrombin

Thrombin

Cardiovascular Disease

Thrombosis

211914-51-1

471.5111

C25H25N7O3

>98% (HPLC)

DMSO: < 1 mg/mL; H2O: < 1 mg/mL

CN1C2=C(C=C(C=C2)C(=O)N(CCC(=O)O)C3=CC=CC=N3)N=C1CNC4=CC=C(C=C4)C(=N)N

β-Alanine, N-[[2-[[[4-(aminoiminomethyl)phenyl]amino]methyl]-1-methyl-1H-benzimidazol-5-yl]carbonyl]-N-2-pyridinyl-

(-20℃)

With Ice Pack

≥ 2 years